Papers

10

Total Citations

67

H-Index

5

About

Andres Correa is a leading urologic oncologist whose research centers on the surgical management of upper tract urothelial carcinoma (UTUC), kidney cancer, and penile cancer. He is a key figure in the ROBUUST 2.0 collaborative group, which has produced landmark studies on robot-assisted nephroureterectomy (RANU) involving over 1,100 patients, establishing benchmarks for surgical and mid-term oncological outcomes. His work has clarified the prognostic impact of diagnostic ureteroscopy, the importance of bladder cuff excision, and the role of adjuvant immunotherapy in high-risk UTUC. Correa has also advanced the technical management of inguinal lymphadenectomy in penile cancer, comparing open and minimally invasive approaches, and has investigated functional outcomes of robotic versus open partial nephrectomy in patients with pre-existing chronic kidney disease. His contributions include developing a nomogram to predict muscle invasion in UTUC and evaluating single-dose intravesical chemotherapy after RANU. With multiple publications in high-impact journals and ongoing leadership in multi-institutional registries, Correa’s research directly shapes clinical decision-making and improves outcomes for patients with complex urologic malignancies.

Research Focus

Key Achievements

5
H-Index
10
Papers
67
Total Citations
7
Avg Citations/Paper
🏆 Most Cited Paper
Robot‐assisted nephroureterectomy: surgical and mid‐term oncological outcomes in over 1100 patients (ROBUUST 2.0 collaborative group)
17 citations · 2024
📈 Most Prolific Year: 2025 (4 Papers)
🤝 Key Collaborators: 88
🏛 Institutions: Fox Chase Cancer Center, Cooper University Hospital, Temple University Health System

Top Papers

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago